This opportunity uses the U01 (Clinical Trial Not Allowed) Research Project – Cooperative Agreements funding mechanism.
The purpose of this initiative is to stimulate basic research, discovery, and early translational research to enable and accelerate the generation of highly efficacious pre-erythrocytic stage malaria vaccines, including sporozoite-based vaccines.
Cross-fertilization and collaboration among investigators from malaria vaccine research and other basic research areas such as parasite biology, parasite genomics, pathogenesis, and host immunology are highly encouraged. The goal is to generate one or more promising vaccine candidates against human malaria that exhibit performance superior to currently available sporozoite-based vaccines and are suitable for further downstream process development and future clinical evaluation.
Funding & Duration
The application budget may not exceed USD $750,000 (approx. AUD $1.1M) in direct costs per year.
The maximum project period is 5 years.
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Submission Requirements & Due Date
- Letter of Intent (LOI) due to Research Services by: 10 December 2019
- Full applications submitted to Research Services for review by: 10 January 2020
- Please email email@example.com if you are considering applying for this scheme.
- See also: Submitting an Application to Research Services for Review